DEA Approves First Ever Clinical Trial With Cannabis

SAN FRANCISCO, CA. --- History has been made with the United States Drug Enforcement Agency (DEA) approving the first ever clinical trial for cannabis. The trial has been approved through the Multidisciplinary  Association for Psychedelic Studies (MAPS) for veterans with treatment resistant PTSD. 

The DEA and FDA have fully approved the clinical trial and will be conducted as a randomized, blinded, placebo-controlled study in 76 US veterans. The study will be funded with a $2.156 million grant from the Colorado Department of Public Health and Environment (CDPHE) to the Santa Cruz based non-profit MAPS, who will conduct the research. 

The study will collect data for safety and efficacy of orally inhaled cannabis with various levels of potency.  The study will be conducted at two principal sites. Marcel Bonn-Miller, Ph.D., will serve as the Coordinating Principal Investigator (PI). Co-Investigators are Sue Sisley, M.D., Ryan Vandrey, and Paula Riggs, M.D., will oversee scientific integrity. 

A monumental step forward for the cannabis movement!